This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IPO Preview: Imperva, NewLink Genetics

Another small offering planned for this week is NewLink Genetics (NLNK - Get Report), a biotech company with oncology products in clinical trials. The Ames, Iowa-based company is hoping to raise $61 million, proposing to sell 5.5 million shares at between $10 and $12 each.

NewLink's lead product is a proposed pancreatic cancer treatment in phase III trials based on its HyperAcute immunotherapy approach, which looks to stimulate the human immune system to combat cancer. The company is pursuing patent protection for specific combination therapies and protection for its novel inhibitor compounds as well as potential second-generation products.

As with all biotechs, NewLink's success depends on receiving approval of its products from the Food and Drug Administration. The company has so far received grants from the National Institute of Health and the Department of Defense, development that impress IPO Desktop's Gaskins.

"I think it's hard to get money from them and it's impressive," he said. Gaskins likes the company and what it is doing, although he is worried that the clinical trials may take longer than planned. There are other companies competing for this market as well, names like Amgen (AMGN - Get Report) and Celgene (CELG - Get Report).

-- Written by Debra Borchardt in New York.

>To contact the writer of this article, click here: Debra Borchardt.

Readers Also Like:

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $156.35 0.00%
CELG $103.22 0.00%
EMC $26.16 0.00%
GRPN $3.38 0.00%
IBM $144.13 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs